期刊文献+

益母草碱及其代谢物在大鼠体内的毒代动力学研究 被引量:5

Toxicokinetics of Leonurine and Its Metabolite in Rats
原文传递
导出
摘要 建立了测定大鼠血浆中益母草碱(1)及其葡萄糖醛酸结合物(2)的LC-MS/MS方法。考察了大鼠单次和连续28 d灌胃给予低、中、高剂量1(200、600和2 000 mg/kg)后1和2在体内的暴露水平,绘制药-时曲线并计算毒代动力学参数。单剂量试验表明,低、中、高剂量组1的AUC分别为(1.946±0.908)、(7.002±2.759)和(26.408±11.491)mol.L-1.h,1在大鼠体内消除行为符合线性动力学模型。多剂量试验表明,低、中、高剂量组1的AUC分别为(2.987±1.089)、(9.083±3.140)和(20.178±7.484)mol.L-1.h。长期大剂量灌胃给予1,1和2均未见在大鼠体内明显蓄积,且试验过程中未见大鼠有明显的毒性反应。 A LC-MS/MS method for determination of leonurine(1) and its metabolite leonurine-O-glucuronide(2) in rat plasma was established.After single-or multiple-dose(once daily for 28 d) ig administration of 1 at low,middle and high doses,the exposure levels of 1 and 2 in rats were investigated.The concentration-time curves of 1 and 2 were drawn and the toxicokinetic parameters were calculated.The AUC of 1 for single-dose ig administration of 200,600,2 000 mg/kg were(1.946±0.908),(7.002±2.759) and(26.408±11.491)μmol·L-1·h,respectively.The results suggested that the elimination behavior of 1 in rats accorded with linear dynamic model.The AUC of 1 for multiple-dose ig administration were(2.987±1.089),(9.083±3.140) and(20.178±7.484)μmol·L-1·h,respectively.No significant accumulation was observed after successive large dose ig administration of 1 in rats.During the experiment there was no significant toxicity in rats.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2012年第6期451-454,474,共5页 Chinese Journal of Pharmaceuticals
基金 国家"重大新药创制"科技重大专项(2009ZX09301-011)
关键词 益母草碱 益母草碱葡萄糖醛酸结合物 LC-MS/MS 毒代动力学 leonurine leonurine-O-glucuronide LC-MS/MS toxicokinetics
  • 相关文献

参考文献7

二级参考文献23

共引文献80

同被引文献75

  • 1陈红宾,周远鹏.五种益母草药理及毒性作用比较[J].北京针灸骨伤学院学报,1994,1(1):38-40. 被引量:8
  • 2晁志,马丽玲,周秀佳.益母草中生物碱成分对大鼠的利尿作用研究[J].时珍国医国药,2005,16(1):11-12. 被引量:65
  • 3孙蓉,孙玲,吴旭东,吕丽莉.复方配伍对益母草致大鼠肾毒性的减毒作用[J].中国药物警戒,2005,2(3):144-147. 被引量:23
  • 4陈怀侠,沈少林,韩凤梅,陈勇.高效液相色谱-电喷雾离子阱串联质谱分析水苏碱及其大鼠体内代谢物[J].药学学报,2006,41(5):467-470. 被引量:13
  • 5Liu XH, Pan LL, Zhu YZ. Active chemical corn pounds of traditional Chinese medicine Herba Le onuri: implications for cardiovascular diseases . Clin Exp Pharmacol P, 2012, 39(3): 274--282.
  • 6Wojtyniak K, Szymaflski M, Matfawska I. Leonu- rus cardiaca L. (Motherwort) : a review of its phy- tochemistry and pharmacology. Phytother Res, 2012, 27(8): 1115--1120.
  • 7Liu XH, Xin H, Hou AJ, et al. Protective effects of leonurine in neonatal rat hypoxic cardiomyocytes and rat infracted heart . Clin Exp Pharmacol P,2009, 36(7): 696-- 703.
  • 8Liu XH, Chen PF, Pan LL, et al. 4-Guanidino-n- butyl syringate (leonurine) protects H9c2 rat ven- tricular cells from hypoxia-indueed apoptosis. J Cardiovasc Pharmacol, 2009, 54(5): 437--444.
  • 9Liu XH, Pan LL, Chen PF, et al. Leonurine im- proves ischemia induced myocardial injury through antioxidative activity [J]. Phytomedicine, 2010, 17 (10) :753--759.
  • 10Xin H, Liu XH, Zhu YZ. Herba leonurine attenu- ates doxorubiein-induced apoptosis in H9c2 cardiac muscle cells . Eur J Pharmacol, 2009, 612(1-- 3) :75--79.

引证文献5

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部